SC
AIM

Stephens Consulting’s AIM ImmunoTech AIM Stock Holding History

Stephens Consulting’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$645 – 537
2023
Q1 		$645 Hold
15
– – ﹤0.01% 497
2022
Q4 		$468 Hold
15
– – ﹤0.01% 480
2022
Q3 		$873 Hold
15
– – ﹤0.01% 527
2022
Q2 		$1.17K Hold
15
– – ﹤0.01% 509
2022
Q1 		$1.59K Sell
15
-15
-50% -$1.29K ﹤0.01% 515
2021
Q4 		$2.76K Buy
+30
New +$4.64K ﹤0.01% 574

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Stephens Consulting's AIM Position: Q2 2023 in Review

Stephens Consulting sold out of AIM ImmunoTech (AIM) in Q2 2023, closing a stake of 15 shares — an estimated $645 sold.

Stephens Consulting first reported a position in AIM in Q4 2021 and held it in 6 quarters. The position peaked at $2.76K in Q4 2021. 30 funds tracked by Wall St. Rank hold AIM as of Q2 2023.

  • Stephens Consulting reported no remaining AIM ImmunoTech position as of Q2 2023 after selling out during the quarter.
  • Stephens Consulting sold 15 AIM ImmunoTech shares in Q2 2023, an estimated $645.
  • Stephens Consulting first reported a position in AIM ImmunoTech in Q4 2021 and held it in 6 quarters.
  • Stephens Consulting's AIM ImmunoTech position peaked at $2.76K in Q4 2021.
  • 30 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2023.

Based on Stephens Consulting's 13F filing for Q2 2023, filed 21 Jul 2023.